Pandemic Darlings The pandemic economy, in original documents
Home Source documents Senate Commerce Committee Statement to Assembly, No. 5017 (November 17, 2025)

Senate Commerce Committee Statement to Assembly, No. 5017 (November 17, 2025)

Summary

Senate Commerce Committee statement to [Second Reprint] Assembly, No. 5017 with committee amendments, State of New Jersey, dated November 17, 2025. The committee reports favorably and with committee amendments Assembly Bill No. 5017 (2R), which exempts insurance-support organizations and national securities associations from provisions of current law that require certain entities to notify consumers of collection and disclosure of personal data. As amended, the bill also exempts certain data from the disclosure requirements, including information treated like protected health information under HIPAA, and expands the definition of de-identified data. The statement says the bill is identical to Senate Bill No. 4259.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Senate Commerce Committee Statement to Assembly, No. 5017 (November 17, 2025).” Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/2025-11-17-scm-a5017-s3-941d2e68e9/, SHA-256 043030ed588be18a94cb0a5b7e148dbe7e432868cc8e6daf0abc64e04762c239.

Full text

     SENATE COMMERCE COMMITTEE

                    STATEMENT TO

                      [Second Reprint]
               ASSEMBLY, No. 5017
                   with committee amendments



 STATE OF NEW JERSEY
                   DATED: NOVEMBER 17, 2025

    The Senate Commerce Committee reports favorably and with
committee amendments Assembly Bill No. 5017 (2R).
    This bill exempts insurance-support organizations and national
securities associations from the provisions of current law that require
certain entities to notify consumers of collection and disclosure of
personal data. Under current law, insurance institutions and other
entities are exempt from those requirements.
    As amended, the bill exempts certain data from disclosure
requirements under current law, including:
    (1) information treated like protected health information collected,
used, or disclosed by a covered entity or business associate under the
"Health Insurance Portability and Accountability Act of 1996"
(HIPAA), when the information is used or disclosed in accordance
with HIPAA and the information is afforded all the privacy protections
and security safeguards of the federal laws and implementing
regulations under HIPAA; and
    (2) human subjects research conducted in accordance with good
clinical practice guidelines issued by The International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use.
    Finally, as amended, the bill expands the definition of de-identified
data under current law to include data de-identified in accordance with
the requirements in HIPAA, where any recipients of that data are
contractually prohibited from attempting to reidentify the data.
    As amended and reported by the committee, Assembly Bill No.
5017 (2R) is identical to Senate Bill No. 4259, which was also
amended and reported by the committee on this date.

COMMITTEE AMENDMENTS:
   The committee amended the bill to:
   (1) exempt certain data from disclosure requirements under current
law, including:
   (a) information treated like protected health information collected,
used, or disclosed by a covered entity or business associate under
                                   2

HIPAA, when the information is used or disclosed in accordance with
HIPAA and the information is afforded all the privacy protections and
security safeguards of the federal laws and implementing regulations
under HIPAA; and
    (b) human subjects research conducted in accordance with good
clinical practice guidelines issued by The International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use; and
    (2) expand the definition of de-identified data under current law to
include data de-identified in accordance with the requirements in
HIPAA, where any recipients of that data are contractually prohibited
from attempting to reidentify the data.

File and source

File
2025-11-17_SCM_A5017_S3.pdf
Size
137,347 bytes
SHA-256
043030ed588be18a94cb0a5b7e148dbe7e432868cc8e6daf0abc64e04762c239
Our copy
2025-11-17_SCM_A5017_S3.pdf
Original
No public link identified.
Back to top